Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
People with hepatitis C have higher cancer rates, even when excluding liver cancer
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough
Another study confirms detrimental effects of delaying hepatitis C treatment
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration
Sofosbuvir-based treatment safe and effective in advanced kidney disease
Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C
